Percheron Therapeutics Future Growth

Future criteria checks 5/6

Percheron Therapeutics is forecast to grow earnings and revenue by 19.8% and 45.3% per annum respectively. EPS is expected to grow by 29% per annum. Return on equity is forecast to be -231.6% in 3 years.

Key information

19.8%

Earnings growth rate

29.0%

EPS growth rate

Pharmaceuticals earnings growth	23.9%
Revenue growth rate	45.3%
Future return on equity	-231.6%
Analyst coverage	Low
Last updated	07 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

OTCPK:PERC.F - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2027	11	6	-38	-38	2
6/30/2026	1	-20	-16	-16	3
6/30/2025	1	-40	-17	-17	2
6/30/2024	3	-12	-10	-10	N/A
3/31/2024	3	-11	-10	-10	N/A
12/31/2023	2	-11	-10	-10	N/A
9/30/2023	2	-11	-9	-9	N/A
6/30/2023	2	-11	-8	-8	N/A
3/31/2023	2	-10	-7	-7	N/A
12/31/2022	2	-8	-7	-7	N/A
9/30/2022	2	-7	-7	-7	N/A
6/30/2022	2	-6	-8	-8	N/A
3/31/2022	1	-7	-8	-8	N/A
12/31/2021	1	-9	-8	-8	N/A
9/30/2021	1	-9	-7	-7	N/A
6/30/2021	1	-8	-6	-6	N/A
3/31/2021	1	-6	-5	-5	N/A
12/31/2020	1	-4	-4	-4	N/A
9/30/2020	1	-5	-4	-4	N/A
6/30/2020	1	-6	-4	-4	N/A
3/31/2020	1	-6	-3	-3	N/A
12/31/2019	1	-6	-3	-3	N/A
9/30/2019	1	-4	-3	-3	N/A
6/30/2019	1	-3	-3	-3	N/A
3/31/2019	0	-3	-3	-3	N/A
12/31/2018	0	-3	-3	-3	N/A
9/30/2018	0	-3	-3	-3	N/A
6/30/2018	0	-2	-2	-2	N/A
3/31/2018	0	-2	N/A	-2	N/A
12/31/2017	0	-2	N/A	-3	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	1	-3	N/A	-3	N/A
3/31/2017	1	-2	N/A	-2	N/A
12/31/2016	1	-2	N/A	-2	N/A
9/30/2016	2	-2	N/A	-2	N/A
6/30/2016	2	-3	N/A	-2	N/A
3/31/2016	3	-1	N/A	-1	N/A
12/31/2015	4	1	N/A	0	N/A
9/30/2015	5	1	N/A	1	N/A
6/30/2015	5	1	N/A	1	N/A
3/31/2015	3	-1	N/A	-1	N/A
12/31/2014	1	-3	N/A	-3	N/A
9/30/2014	1	-3	N/A	-3	N/A
6/30/2014	1	-3	N/A	-3	N/A
3/31/2014	1	-3	N/A	-2	N/A
12/31/2013	1	-3	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PERC.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: PERC.F is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PERC.F is expected to become profitable in the next 3 years.

Revenue vs Market: PERC.F's revenue (45.3% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: PERC.F's revenue (45.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PERC.F is forecast to be unprofitable in 3 years.

Percheron Therapeutics Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Recent updates

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies